Vectura Group plc is pleased to announce the appointment of Will Downie as CEO and Executive Director of the Company with effect from 7th November 2019.
Prior to joining Vectura, Will spent ten years as the Senior Vice President, Global Sales and Marketing at Catalent Inc., one of the world’s largest Contract Development and Manufacturing Organisations (CDMO).
In his role at Catalent, Will led the commercial effort and had responsibility for global sales, marketing and commercial operations activities. During his tenure, he developed an outstanding track record in helping drive the long-term growth of the company, as well as positioning Catalent as one of the leading brands in the pharmaceutical services space. He has a deep understanding of the development and advanced drug delivery market and has amassed significant experience in driving sustained long-term results, as well as building performance-focused organisations and meeting customer needs on a global scale.
Prior to Catalent, Will held positions as Vice President & General Manager, Global Molecular Imaging at GE Healthcare, Vice President Sales EMEA at Amersham Health, and Director of Business Development and Commercial Operations at Quintiles Innovex UK Limited. In his early career, he worked in a range of sales and marketing management positions at both Sanofi and Merck & Co.
Bruno Angelici, Chairman, commented: “I am very pleased to welcome Will Downie as Vectura’s new CEO. He brings a wealth of relevant experience which will help Vectura to grow and deliver on its new strategic focus as a leading inhaled CDMO business.
“I would like to thank Paul Fry for the significant work he has done since stepping into the Interim Chief Executive role and driving the change necessary for Vectura to become a leading player in the inhaled CDMO space. Paul will resume his responsibilities as Chief Financial Officer from 7th November.”
Will Downie commented: “I am delighted to have accepted the role of CEO of Vectura and to have the opportunity to expand and build on its reputation as an inhalation device and formulation specialist. I am looking forward to driving the new business strategy and ensuring the Company achieves its long-term goal of becoming a world-class CDMO organisation in the inhalation space.”
There are no additional details to disclose under Listing Rule 9.6.13 (1) to (6) in respect of the appointment of Will Downie.
For the RNS update, please click here.